{"entity":{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","aka":["HM43239"],"tldr":"Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.","summary":"Tuspetinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Aptose Biosciences Inc., in myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Tuspetinib","url":"https://clinicaltrials.gov/search?intr=Tuspetinib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["mds","cmml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aptose"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03850574"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral kinase inhibitor","mechanism":"A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tuspetinib/","neighbours":{"cancer":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"company":[{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/"}],"trial":[{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct03850574/"}]}}